Stockscreener 앱 받기
32.43
7.69%
-2.70
시간 외 거래:
33.00
0.57
+1.76%
Ultragenyx Pharmaceutical Inc 주식(RARE)의 최신 뉴스
How another firm's FDA approval could mean a big win for Denali Therapeutics - The Business Journals
Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals
Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 52-Week LowShould You Sell? - MarketBeat
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning - Benzinga
Ultragenyx price target raised to $117 from $104 at JPMorgan - TipRanks
Ultragenyx stock hits 52-week low at $36.99 amid market challenges - Investing.com Australia
Ultragenyx stock hits 52-week low at $36.99 amid market challenges By Investing.com - Investing.com South Africa
Ultragenyx CEO Emil Kakkis: ‘Our Future Is In Our Hands’ - insights.citeline.com
Can UX111 Script History As The First FDA-Approved Treatment For Sanfilippo Syndrome Type A? - RTTNews
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Ultragenyx Strengthens Team with Strategic RSU Grants Worth Millions - StockTitan
Ultragenyx price target lowered to $115 from $140 at Piper Sandler - Yahoo Finance
Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight By Investing.com - Investing.com Canada
Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews - Benzinga
Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight - Investing.com
Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren - BioSpace
Trending Report on X-linked Hypophosphatemia Market 2025-2032 - openPR
Have Insiders Sold Ultragenyx Pharmaceutical Shares Recently? - Simply Wall St
Ultragenyx pharmaceutical CFO sells $72,114 in common stock By Investing.com - Investing.com Canada
Ultragenyx pharmaceutical CFO sells $72,114 in common stock - Investing.com India
Ultragenyx Pharmaceutical, Inc. to Host Earnings Call - ACCESS Newswire
Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Growth Potential and Robust Pipeline - TipRanks
FDA grants priority review to gene therapy for Sanfilippo type A - Sanfilippo News
Ultragenyx Pharmaceutical Inc Reports Q4 2024 Revenue of $165 Mi - GuruFocus.com
Ultragenyx pharmaceutical CBO Kassberg sells $253k in stock By Investing.com - Investing.com Australia
Ultragenyx’s chief accounting officer sells $40,710 in stock By Investing.com - Investing.com Australia
Ultragenyx pharmaceutical executive sells $607,881 in stock - Investing.com Australia
Ultragenyx pharmaceutical CBO Kassberg sells $253k in stock - Investing.com India
Ultragenyx EVP Eric Crombez sells $376,584 in stock - Investing.com India
Ultragenyx EVP Eric Crombez sells $376,584 in stock By Investing.com - Investing.com Australia
Ultragenyx pharmaceutical EVP sells $635,836 in stock - Investing.com India
Ultragenyx pharmaceutical EVP sells $635,836 in stock By Investing.com - Investing.com Canada
Ultragenyx CEO Emil Kakkis sells $4.15 million in stock By Investing.com - Investing.com UK
Ultragenyx’s chief accounting officer sells $40,710 in stock - Investing.com
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Ultragenyx EVP Karah Parschauer sells $128,223 in stock By Investing.com - Investing.com Canada
Ultragenyx Loses Bid To Toss Suit Over Henrietta Lacks' Cells - Law360
Ultragenyx EVP Karah Parschauer sells $128,223 in stock - Investing.com India
(RARE) Technical Pivots with Risk Controls - Stock Traders Daily
Y Intercept Hong Kong Ltd Raises Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical’s (RARE) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
10.70%
자본화:
|
볼륨(24시간):